Baseline and early on-treatment immune profiling in patients with pleural mesothelioma on dual immune checkpoint inhibition
Frontiers in Immunology · 20.11.2026 · 17
DOI: 10.3389/fimmu.2026.1874331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 20.11.2026. Verfasst von Solfrid Thunold und 12 weiteren Autor:innen. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pleural mesothelioma (PM) has limited treatment options. Only a minority of patients achieve durable clinical benefit from dual immune checkpoint inhibition (ICI), and biomarkers of response are lacking. In this study, we used RNA sequencing to characterise the tumour microenvironment (TME) at baseline and early on treatment and explored its associations with response to dual ICI.
Methods
Patients with PM treated in second-line with nivolumab/ipilimumab ± UV1 telomerase peptide vaccine underwent tumour biopsies at baseline and week 5. Bulk RNA sequencing was performed, followed by differential gene expression, Hallmark gene set enrichment analyses, xCell cell-type deconvolution, and evaluation of a four-gene inflammatory signature ( CD8A, STAT1, LAG3, CD274 ), each explored in relation to objective response and durable disease control (objective response or stable disease lasting ≥ 24 weeks). Survival analyses were performed to evaluate associations with the ImmuneScore and the four-gene inflammatory signature.
Results
Bulk RNA sequencing was successfully performed in 31 baseline and 23 week 5 biopsies (17 paired). At baseline, interferon/inflammatory Hallmark gene sets were enriched in objective responders. For durable disease control, inflammatory/interferon gene sets were positively enriched, and cell-cycle/proliferation gene sets negatively enriched; only the latter remained after excluding objective responders. Unsupervised hierarchical clustering identified an immune-enriched/stromal-low and a stromal-enriched/immune-poor TME cluster at baseline, and a similar, less distinct pattern at week 5. Four of five objective responders at baseline, and all three objective responders at week 5, were in the immune‐enriched cluster. Objective responders showed higher xCell-derived ImmuneScore and four-gene inflammatory signature scores at both time points, and higher CD8 + T‐cell scores and lower StromaScore at baseline only. Neither baseline ImmuneScore nor the four-gene signature was associated with overall survival. Longitudinal analyses of 17 paired biopsies demonstrated an increase in ImmuneScore in most patients, while changes in StromaScore were heterogeneous.
Conclusion
An immune‐enriched/stromal‐low TME pattern, high four‐gene inflammatory signature scores and enrichment of inflammatory/interferon gene sets were associated with objective response to dual ICI in PM. These exploratory findings require validation in larger cohorts. Clinical trial registration https://clinicaltrials.gov/study/NCT04300244 , identifier NCT04300244.
Zitieren
APA
Thunold, S., Rakaee, M., Giannikou, K., Dalsgaard, A. M., Müller, E., Farooqi, S., Öjlert, Å. K., Meltzer, C., Mikalsen, L. T. G., Hernes, E., Malinen, E., Helland, Å., & Haakensen, V. D. (2026). Baseline and early on-treatment immune profiling in patients with pleural mesothelioma on dual immune checkpoint inhibition. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1874331
Vancouver
Thunold S, Rakaee M, Giannikou K, Dalsgaard AM, Müller E, Farooqi S, et al. Baseline and early on-treatment immune profiling in patients with pleural mesothelioma on dual immune checkpoint inhibition. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1874331
BibTeX
@article{Thunold2026,
author = {Thunold, Solfrid and Rakaee, Mehrdad and Giannikou, Krinio and Dalsgaard, Astrid Marie and Müller, Elisabeth and Farooqi, Saima and Öjlert, Åsa Kristina and Meltzer, Carin and Mikalsen, Lars Tore Gyland and Hernes, Eivor and Malinen, Eirik and Helland, Åslaug and Haakensen, Vilde Drageset},
title = {Baseline and early on-treatment immune profiling in patients with pleural mesothelioma on dual immune checkpoint inhibition},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1874331}
}
EUVIMED